Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study

<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-017-0527-6"><b>here</b>.</a><br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact <u>[email protected]</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slides<u></u></p

Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients

<p><strong>Article full text</strong></p> <br> The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-017-0551-6"><b>here</b>.</a><br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact <u>[email protected]</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slide

Phase information increased sensitivity, and base quality scores increased specificity.

<p>We compared <i>V-Phaser</i> to alternate versions of <i>V-Phaser</i> with specific components disabled. In the No Phase version, <i>V-Phaser</i> called variants without phase information. In the Uniform Errors version, <i>V-Phaser</i> estimated uniform error rates within homopolymer and nonhomopolymer regions without regard to assigned base qualities. In the No Filtering version, <i>V-Phaser</i> did not filter out low quality bases. (<b>A</b>) Phase information increased sensitivity. The version without phase information attained a sensitivity of 90%, but all other versions of <i>V-Phaser</i> used phase information and attained a sensitivity of 97% or more. We calculated sensitivity as the percentage of known variants correctly identified. Data are from WNV mixed population control dataset. (<b>B</b>) Individual base quality scores increased specificity. Among loci with mismatches, the Uniform Errors version had only 91% specificity, but all other versions incorporated base quality scores in their probability model and attained 97% specificity or more. We calculated specificity as the percentage of loci in the control sample correctly identified as having no variants among loci that had at least one candidate variant. Data are from infectious clone (HIV NL4-3) control dataset.</p

NQS filtering improves fit of probability model to data.

<p>(<b>A</b>) Quantile-quantile (q-q) plots under NQS filtering show good fit of the probability model to the observed distribution of errors. Since the probability model is discrete, p values are projected onto a uniform distribution, and the distribution of projected p values is compared with the expected null distribution. See <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1002417#s4" target="_blank">Materials and Methods</a> section for details. (<b>B</b>) In contrast, q-q plots under no filtering show that no filtering skews the calibration of the probability model used by <i>V-Phaser</i>. Q-q plots of models based on subsets of the reads demonstrate that this effect becomes more pronounced with increasing coverage (see <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1002417#pcbi.1002417.s001" target="_blank">Figure S1</a>). Q-q plots are scaled to fit curve, so y = x line is not at a 45 degree angle.</p

Phase increased sensitivity to detect variants.

<p>Phase increased sensitivity to detect variants, as seen over a range of error rates at coverages of 100-fold, 250-fold, and 500-fold. The <i>phased variant detection threshold frequency (VDTF)</i> is the lowest frequency of reads with variants at two specific loci that <i>V-Phaser</i> can distinguish from error among reads that span both loci. The <i>unphased VDTF</i> is the lowest frequency of one variant that <i>V-Phaser</i> can distinguish from error among reads that cover that locus. 100-fold <i>phased</i> sequence coverage achieves comparable detection thresholds as 500-fold <i>unphased</i>. We use Equation 7 to calculate the <i>phased</i> and <i>unphased VDTFs</i>. (See the <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1002417#s4" target="_blank">Materials and Methods</a> section for Equation 7 and its derivation.)</p

Error rates were not uniformly distributed.

<p>Error rates varied by (<b>A</b>) read position, (<b>B</b>) base transition, and (<b>C</b>) base quality score. We counted as errors any mismatches to the consensus assembly for each of the two runs in the control read set under the assumption that the NL-43 infectious clone had no diversity. We defined the read position relative to the beginning or end of the read, whichever was closer. We defined a base transition as a dinucleotide representing the transition from the preceding base to the current base, and we scored a transition as an error if the current base was a mismatch. Base quality scores came from the sequencing process.</p

Phase information increased sensitivity to detect minor variants.

<p>Phase information increased sensitivity to detect low frequency variants, as shown by these histograms of variants under 2.5%. All versions of <i>V-Phaser</i> detected 100% of the variants above 2.5% frequency, so these variants are not shown here. All versions of <i>V-Phaser</i> with phase information (<b>A</b>), (<b>C</b>), and (<b>D</b>) detected most variants below 1% in frequency, but the No Phase version (<b>B</b>) missed many variants below 1% and some variants as high as 2.5%. Data are from control WNV mixed population.</p

Comparison of <i>V-Phaser</i> to other viral variant callers.

<p>Sensitivities and specificities reported across residues interrogated by all programs. Sensitivity is measured as the fraction of the known variants found by each program in the WNV mixed population control data set. Specificity is the fraction of sites not containing known variants that were called as invariant in the HIV NL4-3 control data set; values reported in parentheses include inserted and deleted bases (see <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1002417#s4" target="_blank">Materials and Methods</a>).</p

Rapidly expanding sequence diversity during HIV-1 infection.

<p>Heat maps illustrate sites exhibiting amino acid sequence diversity at days 0, 3, 59, 165, 476 and 1543 post-presentation. Plotted is the percentage of amino acid diversity at each position with respect to the dominant baseline (day 0) amino acid residue. All 3174 amino acids of HIV-1 are represented, with the first amino acid of Gag located in the top left corner of the grid and the last amino acid of Nef located in the bottom right corner. Completely conserved residues are <i>dark blue</i>, low-level variant residues (<10% divergent from baseline) are <i>light blue</i>, moderately variable residues (10–50%) in <i>orange</i>, and highly variant residues (>50%) in <i>red</i>. (<b>A</b>) 0 days p.p., (<b>B</b>) 3 days p.p., (<b>C</b>) 59 days p.p., (<b>D</b>) 165 days p.p., (<b>E</b>) 476 days p.p., (<b>F</b>) 1543 days p.p..</p

Comparison of sequence variant quantification by 454 deep sequencing and by PCR cloning/sequencing.

<p>Orthogonal regression of variant frequency estimates obtained by 454 and clonal sequence data across the highly variable 1544 nucleotide region spanning Vif to Tat in subject 9213 (slope = 1.01; 95% CI, 0.73 to 1.40).</p